(Total Views: 472)
Posted On: 09/09/2019 6:59:45 AM
Post# of 154852
No phase 1. I wonder if it is because Maraviroc has already been used with Regorafenib. Also I don't see ctcs mentioned. I believe we will eventually find out why imo RP was delaying this. Maybe that would be a reason for delaying if no ctcs, this bypasses the need for his other patent, conflict of interest. Maybe he was in talks with someone, they didn't want Regorafenib to be used. Something
Quote:
The Phase 2 study is a single arm study with 30 patients designed to test the hypothesis that the combination of leronlimab, administered as a subcutaneous injection, and Regorafenib, administered orally, will increase progression-free survival in patients with CCR5-positive metastatic colorectal cancer.
(1)
(0)
